
Michael Mina
@michaelmina_lab
Physician-Scientist, MD,PhD. Immunology, Epidemiology, Infectious disease, CSO, CMO. Past: Harvard Faculty. BlueSky @michaelmina.bsky.social
ID: 1094762324097822720
11-02-2019 00:57:32
25,25K Tweet
203,203K Followers
1,1K Following



In our latest FDA Direct conversation, we dive into recent policy changes: ⢠Updates on the Commissionerâs National Priority Voucher program ⢠Review of certain clinical trials involving foreign labs ⢠Dr. Marty Makary insights from the BIO Conference





đ Over 1,200 measles cases in the US so far in 2025 - 95% in people unvaxxed or with unknown status. How did we get here? đ§Ź Our episode breaks down the spread and the science. đ§ Listen: podcasts.apple.com/us/podcast/rol⌠#Measles #Vaccines #PublicHealth #RolinForward #Outbreak


Just had a great conversation with Dr. Michelle Tarver, Director of FDA Medical Devices, about recent innovations in medical devices. From Alzheimer's diagnostics to continuous glucose monitors, CDRH is at the forefront of bringing healthcare home. Exciting times ahead for patient

Great to see FDA leader Dr. Marty Makary talking to CDRH devices director Michelle Tarver. CDRH so often flies under the radar at FDA - I believe at its own peril - would love to see it elevated.

A huge thank you to the two of the 17 ACIP members who were fired by Sec Kennedy for joining us (Charlotte Moser and Dr Jamie Loehr) and to Michael Mina for joining us in this thoughtful discussion on the future of vaccines in this country! podcasts.apple.com/us/podcast/whyâŚ


This is by far the most common vaccine I strongly recommend in ID adult clinical practice. As ID doctors, we see some truly severe cases of zoster, with post-zoster sequelae that may last months or even rarely be permanent. Clinical Infectious Diseases doi.org/10.1093/cid/ciâŚ


âWhy should I trust you?â The podcast which is the brainchild of producer Brinda Adhikari and Maggie Bartlett is pushing new frontiers in communicating public health issues and surfacing all sides I joined them to discuss the good and the bad of the recent ACIP shakeup.